volkow: you are absolutely correct. this is an area of tremendous excitement from the very ly understanding how to optimally use it on patients. because the data is starting to translate into evidence that it could be beneficial, what has happened is that clinicians are ahead of actllwhere thdata is. so it's being offered to a wide variety of patients without sufficient evidence, including the question that you ask. how do you optimally give it without prod ensuring that you're having long-term effe are giving the drug is going to influence your therapeutic response. it's crucial. but like any■ing else, what people get excited about, they want to start believing a little bit in fairy tales. it's not a magic. it's very promising. but we need more research.hank . sen. moran: thank you very much. dr. hodes, i was very interested in your answer to senator collins' question about the state of research regarding alzheimer's. let me ask an additional question. what's the latest in the research, what is the researc's syndrome